Characterization/NN
of/IN
a/DT
novel/JJ
T/NN
lymphocyte/NN
protein/NN
which/WDT
binds/VBZ
to/TO
a/DT
site/NN
related/JJ
to/TO
steroid/thyroid/JJ
hormone/NN
receptor/NN
response/NN
elements/NNS
in/IN
the/DT
negative/JJ
regulatory/JJ
sequence/NN
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
long/JJ
terminal/JJ
repeat/NN
./.

We/PRP
have/VBP
previously/RB
identified/VBN
a/DT
T/NN
lymphocyte/NN
protein/NN
which/WDT
binds/VBZ
to/TO
a/DT
site/NN
within/IN
the/DT
LTR/NN
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
(/(
HIV-1/NN
)/)
and/CC
exerts/VBZ
an/DT
inhibitory/JJ
effect/NN
on/IN
virus/NN
gene/NN
expression/NN
./.
=====
The/DT
palindromic/JJ
site/NN
(/(
site/NN
B/NN
)/)
recognized/VBN
by/IN
this/DT
protein/NN
is/VBZ
related/JJ
to/TO
the/DT
palindromic/JJ
binding/VBG
sites/NNS
of/IN
members/NNS
of/IN
the/DT
steroid/thyroid/JJ
hormone/NN
receptor/NN
family/NN
./.
=====
Here/RB
we/PRP
characterize/VBP
the/DT
T/NN
cell/NN
protein/NN
binding/VBG
to/TO
this/DT
site/NN
as/IN
a/DT
100/CD
kD/NN
protein/NN
which/WDT
is/VBZ
most/RBS
abundant/JJ
in/IN
T/NN
cells/NNS
and/CC
which/WDT
binds/VBZ
to/TO
site/NN
B/NN
as/IN
a/DT
200/CD
kD/NN
complex/NN
./.
=====
This/DT
protein/NN
is/VBZ
distinct/JJ
from/IN
other/JJ
members/NNS
of/IN
the/DT
steroid/thyroid/JJ
hormone/NN
receptor/NN
family/NN
including/VBG
the/DT
COUP/NN
protein/NN
which/WDT
has/VBZ
a/DT
closely/RB
related/JJ
DNA/NN
binding/NN
specificity/NN
./.